SEARCH

SEARCH BY CITATION

References

  • Alt, M., Muller, R. & Kontermann, R.E. (1999) Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. FEBS Letters, 454, 9094.
  • Benedict, C.A., MacKrell, A.J. & Anderson, W.F. (1997) Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay. Journal of Immunological Methods, 201, 223231.
  • Bortoletto, N., Scotet, E., Myamoto, Y., D'Oro, U. & Lanzavecchia, A. (2002) Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells. European Journal of Immunology, 32, 31023107.
  • Bradl, H. & Jack, H.M. (2001) Surrogate light chain-mediated interaction of a soluble pre-B cell receptor with adherent cell lines. Journal of Immunology, 167, 64036411.
  • Carter, P. (2001) Bispecific human IgG by design. Journal of Immunological Methods, 248, 715.
  • Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. & Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood, 99, 754758.
  • Clynes, R.A., Towers, T.L., Presta, L.G. & Ravetch, J.V. (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Medicine, 6, 443446.
  • Dechant, M., Vidarsson, G., Stockmeyer, B., Repp, R., Glennie, M.J., Gramatzki, M., van de Winkel, J.G. & Valerius, T. (2002) Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood, 100, 45744580.
  • Dechant, M., Bruenke, J. & Valerius, T. (2003) HLA class II antibodies in the treatment of hematologic malignancies. Seminars in Oncology, 30, 465475.
  • Elsasser, D., Valerius, T., Repp, R., Weiner, G.J., Deo, Y., Kalden, J.R., van de Winkel, J.G., Stevenson, G.T., Glennie, M.J. & Gramatzki, M. (1996) HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood, 87, 38033812.
  • Fanger, M.W., Shen, L., Graziano, R.F. & Guyre, P.M. (1989) Cytotoxicity mediated by human Fc receptors for IgG. Immunology Today, 10, 9299.
  • Fleit, H.B., Wright, S.D. & Unkeless, J.C. (1982) Human neutrophil Fcγ receptor distribution and structure. Proceedings of the National Academy of Sciences of the United States of America, 79, 32753279.
  • Garcia de Palazzo, I., Holmes, M., Gercel-Taylor, C. & Weiner, L.M. (1992) Antitumor effects of a bispecific antibody targeting CA19–9 antigen and CD16. Cancer Research, 52, 57135719.
  • Gessner, J.E., Heiken, H., Tamm, A. & Schmidt, R.E. (1998) The IgG Fc receptor family. Annals of Hematology, 76, 231248.
  • Glennie, M.J., McBride, H.M., Worth, A.T. & Stevenson, G.T. (1987) Preparation and performance of bispecific F(ab’γ)2 antibody containing thioether-linked Fab’γ fragments. Journal of Immunology, 139, 23672375.
  • Greil, J., Gramatzki, M., Burger, R., Marschalek, R., Peltner, M., Trautmann, U., Hansen-Hagge, T.E., Bartram, C.R., Fey, G.H., Stehr, K. & Beck, J. (1994) The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7. British Journal of Haematology, 86, 275283.
  • Hartmann, F., Renner, C., Jung, W., Deisting, C., Juwana, M., Eichentopf, B., Kloft, M. & Pfreundschuh, M. (1997) Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood, 89, 20422047.
  • Holliger, P., Prospero, T. & Winter, G. (1993) ‘‘Diabodies’’: small bivalent and bispecific antibody fragments. Proceedings of the National Academy of Sciences of the United States of America, 90, 64446448.
  • Hombach, A., Jung, W., Pohl, C., Renner, C., Sahin, U., Schmits, R., Wolf, J., Kapp, U., Diehl, V. & Pfreundschuh, M. (1993) A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. International Journal of Cancer, 55, 830836.
  • Kersey, J.H., Wang, D. & Oberto, M. (1998) Resistance of t(4;11) (MLL-AF4 fusion gene) leukemias to stress-induced cell death: possible mechanism for extensive extramedullary accumulation of cells and poor prognosis. Leukemia, 12, 15611564.
  • Kipriyanov, S.M. & Little, M. (1997) Affinity purification of tagged recombinant proteins using immobilized single chain Fv fragments. Analytical Biochemistry, 244, 189191.
  • Kipriyanov, S.M., Moldenhauer, G., Strauss, G. & Little, M. (1998) Bispecific CD3 × CD19 diabody for T cell-mediated lysis of malignant human B cells. International Journal of Cancer, 77, 763772.
  • Kipriyanov, S.M., Cochlovius, B., Schafer, H.J., Moldenhauer, G., Bahre, A., Le Gall, F., Knackmuss, S. & Little, M. (2002) Synergistic antitumor effect of bispecific CD19 × CD3 and CD19 × CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. Journal of Immunology, 169, 137144.
  • Klingbeil, C. & Hsu, D.H. (1999) Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use. Toxicologic Pathology, 27, 13.
  • Koene, H.R., de Haas, M., Kleijer, M., Roos, D. & von dem Borne, A.E. (1996) NA-phenotype-dependent differences in neutrophil Fcγ RIIIb expression cause differences in plasma levels of soluble Fcγ RIII. British Journal of Haematology, 93, 235241.
  • van der Kolk, L.E., Grillo-Lopez, A.J., Baars, J.W., Hack, C.E. & van Oers, M.H. (2001) Complement activation plays a key role in the side-effects of rituximab treatment. British Journal of Haematology, 115, 807811.
  • Krebber, A., Bornhauser, S., Burmester, J., Honegger, A., Willuda, J., Bosshard, H.R. & Pluckthun, A. (1997) Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. Journal of Immunological Methods, 201, 3555.
  • Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680685.
  • Link, B.K., Wang, H., Byrd, J.C., Leonard, J.P., Davis, T.A., Flinn, I., Hall, W.C., Turner, J.F., Bowles, J., Shannon, M., Levitt, D. & Weiner, G.J. (2001) Prolonged clinical responses in patients with follicular lymphoma treated on a phase I trial of the anti-HLA-DR monoclonal antibody RemitogenTM (Hu1D10). Blood, 98, 244b.
  • Longo, D.L. (2002) DR's orders: human antibody kills tumors by direct signaling. Nature Medicine, 8, 781783.
  • McCall, A.M., Adams, G.P., Amoroso, A.R., Nielsen, U.B., Zhang, L., Horak, E., Simmons, H., Schier, R., Marks, J.D. & Weiner, L.M. (1999) Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Molecular Immunology, 36, 433445.
  • McCall, A.M., Shahied, L., Amoroso, A.R., Horak, E.M., Simmons, H.H., Nielson, U., Adams, G.P., Schier, R., Marks, J.D. & Weiner, L.M. (2001) Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. Journal of Immunology, 166, 61126117.
  • Mack, M., Riethmuller, G. & Kufer, P. (1995) A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 92, 70217025.
  • Milstein, C. & Cuello, A.C. (1983) Hybrid hybridomas and their use in immunohistochemistry. Nature, 305, 537540.
  • Muller, K.M., Arndt, K.M. & Pluckthun, A. (1998) A dimeric bispecific miniantibody combines two specificities with avidity. FEBS Letters, 432, 4549.
  • Nagy, Z.A., Hubner, B., Lohning, C., Rauchenberger, R., Reiffert, S., Thomassen-Wolf, E., Zahn, S., Leyer, S., Schier, E.M., Zahradnik, A., Brunner, C., Lobenwein, K., Rattel, B., Stanglmaier, M., Hallek, M., Wing, M., Anderson, S., Dunn, M., Kretzschmar, T. & Tesar, M. (2002) Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nature Medicine, 8, 801807.
  • van Ojik, H.H. & Valerius, T. (2001) Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy. Critical Reviews in Oncology/Hematology, 38, 4761.
  • Ottonello, L., Epstein, A.L., Dapino, P., Barbera, P., Morone, P. & Dallegri, F. (1999) Monoclonal Lym-1 antibody-dependent cytolysis by neutrophils exposed to granulocyte-macrophage colony-stimulating factor: intervention of FcγRII (CD32), CD11b-CD18 integrins, and CD66b glycoproteins. Blood, 93, 35053511.
  • Peipp, M., Kupers, H., Saul, D., Schlierf, B., Greil, J., Zunino, S.J., Gramatzki, M. & Fey, G.H. (2002) A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Research, 62, 28482855.
  • Pluckthun, A. & Pack, P. (1997) New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology, 3, 83105.
  • Pui, C.H., Gaynon, P.S., Boyett, J.M., Chessells, J.M., Baruchel, A., Kamps, W., Silverman, L.B., Biondi, A., Harms, D.O., Vilmer, E., Schrappe, M. & Camitta, B. (2002) Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet, 359, 19091915.
  • Ravetch, J.V. & Kinet, J.P. (1991) Fc receptors. Annual Review of Immunology, 9, 457492.
  • Sambrook, J. & Russel, D.W. (2001) Molecular Cloning. A Laboratory Manual, 3rd edn. Cold Spring Harbour Laboratory Press, Cold Spring Harbor, NY.
  • Segal, D.M., Weiner, G.J. & Weiner, L.M. (1999) Bispecific antibodies in cancer therapy. Current Opinion in Immunology, 11, 558562.
  • van Spriel, A.B., van Ojik, H.H. & van de Winkel, J.G. (2000) Immunotherapeutic perspective for bispecific antibodies. Immunology Today, 21, 391397.
  • Stadick, H., Stockmeyer, B., Kuhn, R., Schrott, K.M., Kalden, J.R., Glennie, M.J., van de Winkel, J.G., Gramatzki, M., Valerius, T. & Elsasser, D. (2002) Epidermal growth factor receptor and G250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma? Journal of Urology, 167, 707712.
  • Stockmeyer, B., Schiller, M., Repp, R., Lorenz, H.M., Kalden, J.R., Gramatzki, M. & Valerius, T. (2002) Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10 – a humanized human leucocyte antigen DR antibody. British Journal of Haematology, 118, 959967.
  • Tiroch, K., Stockmeyer, B., Frank, C. & Valerius, T. (2002) Intracellular domains of target antigens influence their capacity to trigger antibody-dependent cell-mediated cytotoxicity. Journal of Immunology, 168, 32753282.
  • Truman, J.P., Ericson, M.L., Choqueux-Seebold, C.J., Charron, D.J. & Mooney, N.A. (1994) Lymphocyte programmed cell death is mediated via HLA class II DR. International Immunology, 6, 887896.
  • Tutt, A.L., French, R.R., Illidge, T.M., Honeychurch, J., McBride, H.M., Penfold, C.A., Fearon, D.T., Parkhouse, R.M., Klaus, G.G. & Glennie, M.J. (1998) Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. Journal of Immunology, 161, 31763185.
  • Vaickus, L., Biddle, W., Cemerlic, D. & Foon, K.A. (1990) Interferon-γ augments Lym-1-dependent, granulocyte-mediated tumor cell lysis. Blood, 75, 24082416.
  • Weiner, L.M., Clark, J.I., Davey, M., Li, W.S., Garcia de Palazzo, I., Ring, D.B. & Alpaugh, R.K. (1995) Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and FcγRIII. Cancer Research, 55, 45864593.
  • Weng, W.K. & Levy, R. (2001) Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood, 98, 13521357.
  • Weng, W.K. & Levy, R. (2002) Analysis of IgG Fc receptor FcγRIIIa polymorphism in relapsed follicular non-Hodgkin's lymphoma patients treated with Rituximab. Blood, 100, 157a.
  • White, C.A., Weaver, R.L. & Grillo-Lopez, A.J. (2001) Antibody-targeted immunotherapy for treatment of malignancy. Annual Review of Medicine, 52, 125145.
  • van de Winkel, J.G. & Anderson, C.L. (1991) Biology of human immunoglobulin G Fc receptors. Journal of Leukocyte Biology, 49, 511524.
  • Wurflein, D., Dechant, M., Stockmeyer, B., Tutt, A.L., Hu, P., Repp, R., Kalden, J.R., van de Winkel, J.G., Epstein, A.L., Valerius, T., Glennie, M. & Gramatzki, M. (1998) Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. Cancer Research, 58, 30513058.
  • Yoshida, S., Kobayashi, T., Matsuoka, H., Seki, C., Gosnell, W.L., Chang, S.P. & Ishii, A. (2003) T cell activation and cytokine production via a bispecific single-chain antibody fragment targeted to blood-stage malaria parasites. Blood, 101, 23002306.